基因工程人红细胞生成素对骨髓增生异常综合征患者体内外治疗作用的研究

Study on the Therapeutic Effect of Recombinant Human EPO on MDS In Vivo and In Vitro

EPO体外对26例MDS患者CFU－E的作用及体内用于13例患者的治疗结果显示：（1）EPO对MDS患者CFU－E的作用明显低于对照组；（2）EPO可促进患者CFU－E增殖，这种增殖为剂量依赖型，EPO100u／ml时最强；（3）EPO对CFU－E作用与患者自身CFU－E明显相关。自身CFU－E越接近正常者对EPO反应越好；（4）EPO治疗13例MDS有效3例（23％）。以上结果证明，EPO对于部分MDS患者有效，可作为选择治疗MDS药物。

The therapeutic effect of EPO on the CFU-E of 26 cases of MDS in vitro and 13 cases in vivo were observed. The results showed that (1)the CFU - E of patients with MDS were significantly lower than the control; (2) EPO could improve the dose -dependent CFU-E proliferation of the patients. When the concentration of response to EPO was 100u/ml, the number of CFU-E reached the maximum; (3)The effect of EPO on CFU- E was significantly correlated wlth the CFU - E number of the patients. The patient's number of CFU-E more close to the normal value, the more effective response to EPO; (4)EPO was effective in 3 of the 13 cases of MDS. It proved that EPO was effective for part of patients with MDS and could be used as a clinical drug.